GlassScriptPhysician profile
Bow Young Chung
NPI 1073809570
$86,074.80
in general payments reported to CMS, 2019-2025
29 companies · $31K in 2025
The $31K reported for 2025 was more than what 88% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,631 · 2020: $831 · 2021: $574 · 2022: $8,729 · 2023: $23K · 2024: $21K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Food and Beverage: $3,674 · Consulting Fee: $1,874 · Travel and Lodging: $868 · Education: $9.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,885.00 |
| Food and Beverage | $3,673.58 |
| Consulting Fee | $1,873.98 |
| Travel and Lodging | $867.81 |
| Education | $9.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31,133.48 | 2022-2024 | Jardiance |
| Pfizer INC. | $24,107.77 | 2019-2025 | |
| Bridgebio Pharma, INC. | $20,478.59 | 2025 | Attruby |
| Abbott Laboratories | $5,053.34 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Lilly USA, LLC | $2,990.00 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $337.90 | 2020-2025 | Wainua, Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $240.73 | 2019-2025 | |
| Cvrx, INC. | $207.89 | 2021-2025 | Barostim Neo System |
| Boston Scientific Corporation | $170.62 | 2019-2020 | |
| Medtronic Vascular, INC. | $151.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $144.07 | 2022-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.51 | 2020-2023 | Lifevest |
| Abiomed | $138.82 | 2023 | Impella |
| Paragonix Technologies, INC. | $138.11 | 2024 | Pancreaspak, Liverguard, Lungguard |
| Actelion Pharmaceuticals US, INC. | $119.06 | 2024 | Opsumit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.52 | 2019 | |
| Edwards Lifesciences Corporation | $54.76 | 2020-2021 | |
| Lantheus Medical Imaging, INC. | $50.43 | 2020-2023 | Definity |
| Portola Pharmaceuticals, LLC | $45.53 | 2019 | |
| United Therapeutics Corporation | $39.75 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $39.27 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $37.22 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $31.98 | 2025 | Verquvo |
| Daiichi Sankyo INC. | $28.73 | 2023 | Injectafer |
| Medtronic, INC. | $27.64 | 2024 | Cobalt Dr Mri Surescan |
| Genzyme Corporation | $25.41 | 2024 | |
| Akcea Therapeutics, INC. | $21.39 | 2019 | |
| Medicomp INC | $19.62 | 2023 | Telepatch Cardiac Monitor |
| Arbor Pharmaceuticals, INC. | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bow Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.